# Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

> **NCT00637923** · PHASE2 · COMPLETED · sponsor: **Romark Laboratories L.C.** · enrollment: 112 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Placebo
- **BIOLOGICAL:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00637923
- **Lead sponsor:** Romark Laboratories L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2014-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637923, "Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00637923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*